Some Women Are Football Widows... I'm a Biotech Widow

It's true! Gary told me a few days ago that I was about to "lose him" again. This always means something big is going on at work and in light of the recent collaboration news, I can really see why he's busy. Losing him means we'll see each other for a few minutes in the morning when he leaves for work at 6:30am and maybe at night as I am drifting off to sleep and he walks in the door at 10pm. Funny thing is, the last time we were in one of these cycles, Madison turned to me one day and said "when is daddy coming home from his business trip?" Well actually he wasn't out of town, he was just working so much that the kids were asleep when he got home and not yet awake when he left in the morning. Oh well, it's all in the name of saving lives and improving the quality of life. So I'll keep that in mind the next time I am heating up Gary's dinner at 9pm.

It's Cloudy Outside Today but I'm Seeing Only Blue Skies :)

Nuvelo Shares Soar on Bayer PartnershipThursday January 5, 11:32 am ET
Nuvelo Shares Jump to 52-Week High on Drug Collaboration With Bayer

NEW YORK (AP) -- Nuvelo Inc. shares surged to a 52-week high Thursday after the biotech drug developer signed on Bayer AG as a partner for its experimental blood clot treatment.
The German drug company agreed to pay Nuvelo up to $385 million for selling rights outside the United States -- $50 million up front, along with up to $335 million as certain development and sales benchmarks are reached.
Nuvelo will also receive royalties of up to 37.5 percent on Bayer's sales.
Nuvelo shares surged about 42 percent to $12.77 in Nasdaq morning trading, before settling around $12.40 more recently. The trading volume was 5.8 million, compared with the daily average of 304,244.
The stock's previous 52-week high was $10.35 in September.
The drug at the center of the deal -- alfimeprase -- works by degrading fibrin, a protein involved in the formation of blood clots. Nuvelo's lead drug candidate, it is in late-stage trials testing it as a treatment for certain blood clots in the legs and for catheter obstruction.
The companies said they also plan to develop the drug for stroke and another type of clot called a deep vein thrombosis. Bayer agreed to take on 40 percent of the costs for global development of the drug.
San Carlos, Calif.-based Nuvelo predicted that it will receive $90 million from the partnership this year, including the upfront payment.

We call her "M. Diddy"

 

Hanukkah with Pop Pop